U.K. Watchdog Says GSK Infringed Competition Law With “Pay-For-Delay” Deals
This article was originally published in The Pink Sheet Daily
Executive Summary
The U.K.'s Office of Fair Trading is proceeding with its action against GlaxoSmithKline, alleging it held back generic competition to its best-selling antidepressant paroxetine from 2001 to 2004 through agreements with generic drug firms.
You may also be interested in...
Servier’s EU Nightmare Continues As Commission Moves To Shut Down Disputed IP Practices
The European Commission’s allegations against Servier for alleged patent abuses could help to clarify the law in this area for original product manufacturers in the long term.
GSK’s DoJ Settlement Requires Execs To Forfeit Bonuses If Misconduct Occurs
GlaxoSmithKline pleads guilty to promoting Paxil and Wellbutrin off-label and failing to report Avandia safety data to FDA; civil portion of settlement resolves off-label and kickback allegations involving nine products. New corporate integrity agreement gives OIG authority to require a recall.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.